Edition:
United Kingdom

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

13.54USD
8 Dec 2017
Change (% chg)

$0.47 (+3.60%)
Prev Close
$13.07
Open
$13.10
Day's High
$13.77
Day's Low
$13.04
Volume
262,736
Avg. Vol
245,467
52-wk High
$28.49
52-wk Low
$8.62

Summary

Name Age Since Current Position

Derek Chalmers

53 President, Chief Executive Officer, Director

Mani Mohindru

45 2017 Chief Financial Officer, Chief Strategy Officer

Michael Lewis

65 2016 Chief Scientific Officer

Frederique Menzaghi

50 Vice President, Research & Development

Joseph Stauffer

50 2014 Chief Medical Officer

Harrison Bains

73 2014 Independent Director

Jeffrey Ives

66 2014 Independent Director

Dean Slagel

47 2005 Independent Director

Martin Vogelbaum

53 2010 Independent Director

Biographies

Name Description

Derek Chalmers

Dr. Derek Chalmers, Ph.D. serves as a President, Chief Executive Officer and a Director at Cara Therapeutics, Inc. Dr. Chalmers has over 20 years’ experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding company, Dr. Chalmers co-founded Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a drug discovery and development company, and served as its Vice President and Executive Director from June 1997 until May 2004. Dr. Chalmers holds a D.Sc. and Ph.D. in Pharmacology from the University of Glasgow.

Mani Mohindru

Dr. Mani Mohindru, Ph.D., serves as Chief Financial Officer, Chief Strategy Officer of the Company. effective from August 15, 2017. Dr. Mohindru brings more than a decade of leadership experience in the biopharmaceutical industry to Cara. Most recently, she served as Chief Strategy Officer at Curis, Inc. (Nasdaq:CRIS), where she was instrumental in the development and management of overall corporate strategy. She was also responsible for the company's engagement with the investment community, building extensive relationships with industry analysts and investors. Earlier in her career, Dr. Mohindru spent several years as an equity research analyst covering the biotechnology sector at ThinkEquity, LLC, Credit Suisse and UBS. She also co-founded Immtox LLC, a privately held biotechnology company, and was a healthcare industry consultant at Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health). Dr. Mohindru received her Ph.D. in neurosciences from Northwestern University.

Michael Lewis

Dr. Michael E. Lewis is the Chief Scientific Advisor at Cara Therapeutics, Inc. Previously, he has co-founded Cephalon, Inc. and served as Director of Pharmacology and Senior Director of Scientific Affairs. He also co-founded and served as Chief Scientific Advisor to Adolor Corporation and also participated on their analgesics development team and assisted in pre-initial public offering (IPO) financing and corporate partnering presentations. He was co-founded Arena Pharmaceuticals, and served as a pre-IPO Director and Chief Scientific Advisor to Arena. He is a Director of PolyMedix, Inc., a privately held biotechnology company that is developing antimicrobial agents based on a novel computational chemistry platform.

Frederique Menzaghi

Dr. Frederique Menzaghi, Ph.D., serves as a Vice President Research and Development of Cara Therapeutics, Inc. She has seventeen years of drug development and management experience in biotechnology in the field of ion channels and GPCRs. She previously served as Vice President Pharmacology and Business Development at Psychogenics Inc., and was the Research Director of In Vivo Pharmacology at Arena Pharmaceuticals. Prior to that, she established and directed a preclinical research laboratory at SIBIA Neurosciences. She has experience with corporate partnering with pharmaceutical companies including Eli Lilly and J&J. She received her Ph.D. in Neurosciences from the Louis Pasteur University, Strasbourg, France and a Master of Science in Clinic al Psychology from the University of Nancy.

Joseph Stauffer

Dr. Joseph William Stauffer D.O. serves as a Chief Medical Officer of the Company. Dr. Stauffer has over 20 years of medical practice and clinical research experience. Prior to joining Cara, he served as Chief Medical Officer at the following public and private biopharma and specialty pharma companies: Ikaria from 2012 to 2014, PharmacoFore, Inc. from 2011 to 2012 and DURECT Corporation from 2009 to 2011. From 2004-2009, he was Chief Medical Officer at Alpharma Pharmaceuticals and the architect of the clinical development program for EMBEDA, the first abuse-deterrent long-acting opioid analgesic approved by the FDA. Dr. Stauffer began his industry career as Global Medical Director at Abbott Laboratories. Prior to Abbott he worked at FDA as a Medical Review Officer in the Anti-Inflammatory & Analgesic Division of the Center for Drug Evaluation and Research. He serves as an expert clinical research reviewer for the European Commission. Dr. Stauffer maintains an appointment as part-time Assistant Professor in the Department of Anesthesiology and Critical Care Medicine at the Johns Hopkins University School of Medicine. Dr. Stauffer completed his Anesthesiology residency at Johns Hopkins University Hospital.

Harrison Bains

Mr. Harrison M. Bains, Jr., serves as an Independent Director of the Company. From 1988 through his retirement in 2004, Mr. Bains served in multiple roles at Bristol Myers Squibb Company, including Vice President, Treasurer and acting Chief Financial Officer. Mr. Bains’s career also includes serving as Senior Vice President of the Primary Industries group at Chase Manhattan Bank and 11 years with RJR Nabisco and two of its predecessor companies as Senior Vice President and Treasurer. He currently serves as a director of BG Medicine, Inc., as a director and former chairman of the Mercer Funds, Inc., a registered investment company, and as a director of Bank of America Funds. He has served as a member of the board of trustees of the Park Avenue Armory since October 2007 and the Civil War Trust since September 2007, and previously served as a member of the board of trustees of the University of Redlands from October 1989 to May 2013. Mr. Bains earned an M.B.A from the University of California, Berkeley and a B.A. in economics from the University of Redlands. He also completed the Advanced Management Program at Harvard Business School.

Jeffrey Ives

Dr. Jeffrey L. Ives, Ph.D., serves as an Independent Director of the Company. From 2008 until 2013, Dr. Ives served as the Chief Executive Officer of Satori Pharmaceuticals, Inc., a neurodegenerative disease company focused on discovery and development of breakthrough therapies for the treatment and prevention of Alzheimer’s disease. Prior to Satori, Dr. Ives led the CNS, pain and oncology research teams at Pfizer for over two decades and, from 2001-2007, served as a Senior Vice President leading the global Pharmacokinetics, Dynamics and Metabolism organization. Dr. Ives received his doctorate and master degrees from Yale University and received his bachelor of arts degree from Colgate University.

Dean Slagel

Mr. Dean Slagel serves as an Independent Director of the company since February 2005. Mr. Slagel is the Managing Director of Esperante BV and Esperante AB, life sciences venture investment companies founded in September 2004 and June 2005, respectively. From September 1995 to September 2004, Mr. Slagel served as the Global Business Development Director of Ferring Pharmaceuticals, a specialty biopharmaceutical group then based principally in the UK, France and Denmark.

Martin Vogelbaum

Mr. Martin Vogelbaum serves as an Independent Director of the company. Mr. Vogelbaum has served as a partner of Rho Ventures since 2005 and primarily focuses on investments in biotechnology, biopharmaceuticals and medical devices. He has more than 19 years of experience investing in the life sciences sector, having been involved with companies at all stages of development, including co-founding more than a half dozen companies. Mr. Vogelbaum currently serves as a director of Inotek Pharmaceuticals Corporation. In 2014, Mr. Vogelbaum served as a member of the board of directors of Nephrogenex, Inc. and from 2007 to 2010, Mr. Vogelbaum served as a member of the board of directors of Middlebrook Pharmaceuticals, Inc. Prior to his venture capital career, he was a research associate in the bone marrow transplantation unit at Memorial-Sloan Kettering Hospital, where he conducted research in graft-versus-host-disease (GVHD). Mr. Vogelbaum received his A.B. in biology and history from Columbia University.

Basic Compensation